Adimmune

Historical Events

2013 - Present

Flu vaccine receives EMA certification for Austria, Ireland, Spain, Portugal, Netherland, Belgium, Luxemburg, Switzerland, and Scandinavian states of Sweden, Norway, Denmark, and Finland

  1. 2017
    • Began commercial shipment of PSC tetravalent influenza vaccine to the US
    • Began commercial shipment of Techdow low molecule Enoxaparin sodium to Europe.
    • Completed Brazilian ANVISA GMP inspection
  1. 2016
    • Filed for tetravalent influenza vaccine NDA for marketing authorization in Taiwan
    • Passed US FDA GMP inspection and certification
    • Began commercial shipment of trivalent influenza vaccine to China
  1. 2015
    • Signed Cooperation Framework Agreement with Kitasato Daiichi Sankyo Co., Ltd.
    • Received EMA GMP certification for the fill and finish facility
    • Acquired cell cultured Japanese encephalitis vaccines import certificate for Valneva SE in Scotland
    • Acquired trivalent influenza vaccine marketing authorization for China
    • Complete enrollment of Phase III clinical trial for tetravalent influenza vaccine in Taiwan
    • Agrimmune Corporation established as a subsidiary of Adimmune
    • Complete acceptance of phase III clinical trial for tetravalent influenza vaccine
    • Received TFDA validation for GDP standard of excellent pharmaceutical transportation
  1. 2014
    • Enimmune Corporation established as a subsidiary of Adimmune
    • Completed Phase II clinical trial for N7N9 bird influenza virus vaccine
    • Received PIC/S GMP certification for flu antigen production plant and filling plant after passing inspection from TFDA
    • Completed trivalent influenza flu vaccineenrollment of 1200 human subjects for Phase III clinical trial in Guanxi, China
    • Signed fill and finish services contract with Protein Sciences Corp. to provide professional aseptic filling and finishing services for the new tetravalantinfluenza vaccine
    • Receive Talent Quality-Management System (TTQS) Review Copper Award from Workforce Development Agency
  1. 2013
    • Flu vaccine received EMA marketing authorizations for Austria, Ireland, Spain, Portugal, Netherland, Belgium, Luxemburg, Switzerland, and Scandinavian states of Sweden, Norway, Denmark, and Finland
    • Signed cooperation contract with the Natioal Health Research Institute for “Licensing of the results for the Phase I clinical trial of enterovirus 71 vaccines”
    • Signed Cooperating contract for sterile filling service with Techdow Pharm Co., Ltd.
    • Received approval for trivalent influenza vaccine Phase III clinical trial from CFDA in China
    • Signed cooperation agreement with UMN, a global leader in recombinant protein vaccine manufacturing
2008 - 2012

Receive Taiwan Patent for Japanese Encephalitis DNA vaccine (no. I 302166)

  1. 2012
    • IPO listing on the main board of the Taiwan Stock Exchange
    • New aseptic pre-filled syringe line received cGMP certification from TFDA
  1. 2011
    • Received National Biotech-Medical Quality Gold Award
    • Passed EMA Plant Inspection and received certification
  1. 2010
    • Received Merit Medal Award from Executive Yuan for work on pandemic control of H1N1 flu
    • IPO listing on Taiwan’s emerging stock market
    • Received Deloitte Asia-Pacific High-Tech High-Growth Evaluation, ranked 8th in Taiwan, 64th in the Asia-Pacific region
  1. 2009
    • Completion of EU GMP standard flu vaccine plant
    • Received Ministry of Economy certification as bio-technnology company in accordance with the New Biotechnology Ordinance
  1. 2008
    • Acquired Taiwan patent for Japanese Encephalitis DNA vaccine (no. I 302166)
    • Dr. Chan Chi-Shean, former Director-General of Health Administration, elected as Chairman
    • New equity investments from China Steel Corporation, Taiyen Biotech Co.,Ltd, Fubon Venture Capital, Boston Venture Capital, Shengyang Venture Capital, Japan BHP Venture Capital, totaling NT$1.316 bill
2000 - 2007

Change English name to “Adimmune Corporation”

  1. 2007
    • Sign strategic alliance agreement with Crucell B.V., Netherland, obtain authorization for Virosome adjuvant technology
    • Crucell B.V. became a new strategic shareholder, investing NT$384 million
    • Professor Lee Ming-liang, former Director-General of Health Administration, elected Chairman
  1. 2006
    • First export of influenza vaccine to Macau
  1. 2005
    • Signed technology transfer agreement with Kitasato Institute
    • Received the “Sullivan & Frost Award for Growth Strategy”
    • Received the Ministry of Economic Affair’s “Industrial Technology Development Plan for Cell Culture Process Platform of Japanese Encephalitis Vaccine” grant
    • First domestic non-serum cell cultured SARS prototype vaccine developed
  1. 2004
    • Technology transfer for Diphtheria vaccine from BDC
    • Initiated SARS vaccine development project (SVAC09)
  1. 2003
    • Passed 3-stage Danish SSI GMP validation process inspection, received PPD import certification
  1. 2002
    • Completion of Phase I influenza vaccine technology transfer from Katasato Institute
    • Introduction of Adimmune/Kitasato influenza vaccine in Taiwan market, received government purchasing contract for 358,000 doses
    • Signed licensing contract for human biological agent manufacturing technology with Taiwan CDC
  1. 2001
    • Changed company’s English name to “Adimmune Corporation”
    • Imported Kitasato’s influenza vaccine for aseptic filling
    • New equity investments from National Development Fund, Yaohua Glass Corporation, Bank of Communications and Nanho Development Co., Ltd.
1965 - 1999

“Kuo Kwang Serum and Vaccine Manufacture Co., Ltd.” was founded in Shulin Township, Taipei County with an initial capital of NTS3 million.

  1. 1998
    • Received the Ministry of Economic Affair’s “Industrial Technology Development Plan for Production of Japanese Encephalitis Vaccine by Cell Culture Process” grant
    • Received “the 8th Annual Award for Biotechnology Industry Development” by Taiwan Bio Industry Organization
  1. 1991
    • Completion of Tanzi compus construction. Production in Shulin compus transferred to the new GMP grade facility, continuing manufacturing and sales of human and animal vaccines
  1. 1970
    • Technology transfer for vaccine manufacturing technologies from Kitasato Institute
  1. 1967
    • Signed official technical support and import/export agreement with Kitasato Institute, with advisory support for the establishment of serum vaccine manufacturing technology
  1. 1965
    • “Kuo Kwang Serum and Vaccine Manufacture Co., Ltd.” was founded in Shulin Township, Taipei County with an initial capital of NTS3 million.